tbuckley/cabot-search huggingface dataset:
MLL Rearrangements in Childhood Acute Lymphoblastic Leukemia: Clinical and Genetic Features of a Distinct Disease Entity
Authors: Maria Ampatzidou, Stephanos I. Papadhimitriou, Loizos Petrikkos, Dimitrios Pavlidis, Konstantinos Tsitsikas, Vassilios Papadakis, George Paterakis, Sophia Polychronopoulou
Journal: Blood (2014)
NCO-11TUMOR VOLUMETRIC AND TEXTURAL FEATURE PREDICTORS OF NEUROCOGNITIVE IMPAIRMENT IN PATIENTS WITH TEMPORAL LOBE GLIOMA
Authors: Kyle Noll, Shivali Narang, Juan Martinez, Ganesh Rao, Jeffrey Wefel, Arvind Rao
Journal: Neuro-Oncology (2015)

BACKGROUND: To determine whether computationally derived image-based textural and volumetric tumor features can predict cognitive impairment in patients with temporal lobe glioma. METHODS: Treatment naive patients with glioma (n = 69; 64% glioblastoma; 74% left temporal) completed neurocognitive testing [WAIS-III Digit Span (DS); Controlled Oral Word Association (COWA); HVLT-R Total Recall; Trail Making Test A & B (TMT)]. Demographically adjusted scores that were at or below   0.74). Volumetric and textural tumor features appear predictive of neurocognitive impairment in patients with glioma, with inclusion of textural indices conveying at least marginal improvement in classification accuracy.
Detection of Microdeletions and Amplifications in Primary Human Acute Myeloid Leukemia (AML) Genomes Using Ultradense Oligomer Tiling Path Arrays and Comparative Genomic Hybridization (CGH).
Authors: Matthew J. Walter, R. R. Ries, X. D. Li, W. J. Shannon, J. Payton, C. D. Bloomfield, K. Mrozek, A. S. Ruppert, J. DiPersio, D. Link, M. Tomasson, T. Graubert, H. McLeod, S. Devine, M. Watson, S. Heath, J. Baty, K. Trinkaus, J. Armstrong, E. Mardis, R. Wilson, R. Selzer, T. Richmond, P. Eis, T. J. Ley
Journal: Blood (2005)
Inhibition of mTOR Kinase Pathway Selectively Sensitizes Acute Myeloid Leukemia Cells to Cytarabine-Induced Apoptosis.
Authors: Piotr Smolewski, Agnieszka Janus, Barbara Cebula, Anna Linke, Krzysztof Jamroziak, Tadeusz Robak
Journal: Blood (2005)
MNGO-12FACTORS ASSOCIATED WITH LOW SOCIOECONOMIC STATUS PREDICT POOR POSTOPERATIVE FOLLOW-UP AFTER MENINGIOMA RESECTION
Authors: Arash Nayeri, Philip Brinson, Marc Prablek, Lola Chambless
Journal: Neuro-Oncology (2015)

OBJECTIVES: Appointment non-attendance and poor follow-up have been cited as contributors to poor patient outcomes and as unnecessary financial burdens on the healthcare system. A number of demographic factors, particularly those associated with low socioeconomic status (SES), have been associated with poor follow-up in different patient populations. We sought to quantify the rates of loss of follow-up after meningioma resection at our institution and to identify any key demographical associations. METHODS: We conducted a retrospective cohort study on 281 patients surgically treated for an intracranial meningioma at a single institution between 2001 and 2013. Records of clinical and radiographic data were retrospectively obtained from the electronic medical record. A Loss of Follow-up variable was created based on patient clinical follow-up within the first postoperative year. Pearson's correlation was used to compare loss of follow-up with continuous variables. Fisher's exact test was used to test for any association between race, gender, educational attainment, insurance status, history of illicit substance and tobacco use, or continued alcohol abuse with loss of follow-up. RESULTS: Overall, 53 (19%) patients demonstrated loss of follow-up within the first postoperative year. A history of tobacco use (p < 0.0001), ongoing alcohol abuse at time of presentation (p = 0.0014), Medicaid coverage (p < 0.0001), and lack of a college degree (p < 0.0001) were all found to be predictors of loss of follow-up at a statistically significant level. CONCLUSIONS: A number of factors associated with low SES are predictors of poor clinical follow-up after meningioma resection. The health risk of poor follow-up in this patient population is significant and increased measures are needed to ensure regular appointment attendance.
Sustained Elevation of Adenosine-ADORA2B Signaling Promotes Chronic Pain through Neuro-Immune Interaction in Sickle Cell Disease
Authors: Morayo G. Adebiyi, Xia Hu, Jialie Luo, Kaiqi Sun, Thanh-Thuy T. Le, Yujin Zhang, Hongyu Wu, Hong Liu, Aji Huang, Rodney E. Kellems, Michael R. Blackburn, Edgar T. Walters, Hongzhen Hu, Yang Xia
Journal: Blood (2015)
Is there an advantage to adding inferior vena cava filter (IVCF) placement to anticoagulation with fondaparinux in patients with cancer and venous thromboemboli (VTE): Results of the Cancer and Thrombosis (CAT) prospective randomized clinical trial (RCT).
Authors: M. F. Barginear, R. J. Gralla, M. Akerman, M. Lesser, T. P. Bradley, I. Shapira, N. J. Nier-Shoulson, C. R. Greben, D. R. Budman
Journal: Journal of Clinical Oncology (2011)

9063 Background: The efficacy and safety of IVCF addition to parenteral anticoagulation (AC) in treating cancer patients with VTE remains controversial and no RCTs have been conducted in this population. We initiated this prospective RCT to determine if the addition of IVCF placement is advantageous in cancer patients. Methods: 64 patients with a DVT (86%) and/or PE (55%) were randomly assigned (1:1) to receive AC with fondaparinux sodium (FS) [5mg, 7.5mg or 10mg] with or without an IVCF. Endpoints included: rates of complications by treatment arm; recurrent or residual DVTs or PEs on days 14, 30, and 56; and survival rates. Results: 64 patients were randomized and 63 evaluated. Cancer types included: lung (25%); breast (18%), colon (14%), pancreas (14%), lymphoma (8%), ovarian (6%), and 15% with other cancers. ECOG performance status: 0 or 1 in 44%; 2 in 47%; and 3 in 9%. 8 patients (12.5%) had stable brain metastases. Findings included: no patient had a recurrent DVT; 2 (3%) patients had new PEs (one in each treatment arm). Major bleeding occurred in 2 patients (6%) receiving AC only and 1 (3%) patient receiving AC+IVCF; minor bleeding occurred in 2 patients in each treatment arm. 2 (7%) patients had complications from the IVCF which included an occlusion requiring a thrombectomy and prolonged bleeding at the incision site requiring prolonged hospitalization. Median survivals were 493 days in the AC only arm 266 days for AC + IVCF (p<0.57). Conclusions: 1) No advantage was found for placement of an IVCF in addition to AC with FS. 2) While a trend toward lessened survival was seen in the IVCF+AC arm, it is difficult to say that this is treatment related due to the heterogeneous patient population. 3) With the cost and invasiveness of IVCF placement and without a benefit in recurrent PE rate or safety, IVCF should not routinely be added to AC for cancer patients with DVT or PE. This study is the only prospective RCT evaluating AC plus IVCF in cancer patients. Further studies would be needed to see if any subpopulation benefits from IVCF placement, although no such group was indicated in this trial.
Acute Calculous Cholecystitis With Intrahepatic Gallbladder Perforation
Authors: Kishore G. S. Bharathy, Deeplaxmi Borle, Niteen Kumar
Journal: JAMA Surgery (2017)

A man in his 50s presented with right upper abdominal pain he had experienced for 20 days, with high-grade fever and chills since the first week. Ultrasonography of the abdomen revealed a large hypoechoic area in the right lobe of the liver along with gallstones. What is your diagnosis?
Heterogeneity in Infants with Acute Myeloid Leukemia: Retrospective Analysis of a Japanese Nationwide Survey
Authors: Akira Shimada, Daisuke Tomizawa, Akitoshi Kinoshita, Kazuko Hamamoto, Ichiro Tsukimoto, Atsushi Ogawa, Takashi Taga, Toshihiko Imamura, Akio Tawa, Keizo Horibe, Tomohiko Taki, Yasuhide Hayashi, Souichi Adachi
Journal: Blood (2011)
Financial burden experienced by patients undergoing treatment for malignant gliomas: Updated data.
Authors: D. Jacobs, B. V. Stell, S. A. Grimm, A. Rademaker, L. Rice, M. A. Schwartz, J. Chandler, K. Muro, M. H. Marymont, I. B. Helenowski, L. I. Wagner, J. J. Raizer, C. L. Bennett
Journal: Journal of Clinical Oncology (2011)

e19571 Background: Patients undergoing treatment for malignant gliomas often face staggering costs beyond traditional insurance coverage. These “out-of-pocket” costs are organized into these three categories: 1) direct medical costs (e.g. hospital stays, physician visits, laboratory testing); 2) direct non-medical costs (e.g. transportation, parking, food); and 3) indirect costs (e.g. lost wages). The purpose of this study is to gain prospective data regarding monthly expenditures associated with treatment of brain tumors. Methods: Patients with stage III or IV malignant glioma within 6 months of diagnosis or relapse were eligible for this study. Weekly logbooks were issued to patients to record out-of-pocket costs during treatment for six months or until progression. Both direct medical expenses and direct non-medical expenses were measured. Results: Thirty-six patients provided an average of 12 weeks worth of cost data each. Of the patients in this sample, 59% were male, 81% were married, 50% reported annual income greater than $75,000, and the average age was 53. Mean monthly out-of-pocket costs for this population were $2,153. These monthly expenditures are higher than those measured for select other cancer populations seen in the Robert H. Lurie Comprehensive Cancer Center, including lymphoma and breast cancer patients ($1,888 and $1,455 respectively (W. S. Oatis, N. Nonzee, T. Markossian, et al. Interpreting out-of-pocket expenditures for cancer patients: The importance of considering baseline household income information. J Clin Oncol. 27:15s, 2009 (suppl; abstr 6541).) The greatest monthly costs were acquired in the form of medication co-payments ($499), transportation ($382) and hospital bills ($292). Conclusions: Out-of-pocket costs incurred by malignant glioma patients are particularly high. The treating physician must be aware of the particularly high financial burden on patients and their families undergoing treatment for malignant gliomas and work with them to minimize costs as well as understand the different expense areas. These issues are important with changes in health care coverage.
Separation of GvH- and GvL-Immune Responses in Allogeneic Stem Cell Transplantation by CD95-Mediated Depletion of Alloreactive T-Cells Using CD178 Based Proapoptotic Chimeric Molecules.
Authors: Marcus Kaltwasser, Matthias Lehne, Harald Wajant, Christoph Huber, Udo F. Hartwig
Journal: Blood (2004)
Effect of zoledronic acid and biochemical relapse in treatment-naive patients with bone-metastatic prostate cancer.
Authors: Hideyasu Matsuyama, Masahiro Nozawa, Takeshi Inagaki, Kazuhiro Nagao, Isao Hara, Hirotsugu Uemura
Journal: Journal of Clinical Oncology (2012)

136 Background: Recent reports suggest that zoledronic acid have anti-proliferative activity, and that bone metabolism markers predict patient outcome in prostate cancer. Aims of this study are if bone metabolism markers may predict patient outcome who are treated with zoledronic acid concomitant with androgen deprivation therapy (ADT), and if zoledronic acid has oncological benefit in patients with metastatic prostate cancer. Methods: A multi-institutional prospective phase II study was conducted for 54 treatment-naïve patients with bone-metastatic prostate cancer who were treated with zoledronic acid concomitant with ADT (ADT-Z group). Median age, baseline PSA of the patients were 72, and 249ng/ml, respectively. Patients were treated with zoledronic acid (4 mg iv every 4 weeks) in combination with bicalutamide (80mg po) and goserelin acetate (10.8mg sc every 3 months), and followed with a median follow-up of 24.6 months. Serum bone metabolism markers, including bone-specific alkaline phosphatase (BAP) and cross-linked C-terminal telopeptides of type I collagen (I-CTP) and urine levels of cross-linked N-terminal telopeptides of type I collagen (NTx), were measured before treatment followed by every 3 months thereafter, and were compared with biochemical relapse (BCR). BCR of those patients was compared with that of 180 patients who were treated with ADT alone (ADT group) as historical control. Results: Baseline NTx (&gt;100), baseline PSA (&gt;225), EOD (&gt;2) were significantly linked with BCR. Baseline NTx (&gt;100) was an independent predictor for BCR in multivariate analysis (p=0.02). Time to BCR was significantly longer in ADT-Z group than that in ADT group (p&lt;0.0001, median TTP: not reached in ADT-Z vs. 15.4 months in ADT). Conclusions: Zoledronic acid may improve patient prognosis, and baseline NTx may be a useful predictor for BCR in treatment-naïve metastatic prostate cancer patients with zoledronic acid combined with ADT.
HCP-18REGIONAL DISPARITIES IN HOSPITALIZATION CHARGES IN PATIENTS UNDERGOING CRANIOTOMIES FOR BRAIN TUMOR RESECTION IN NEW YORK STATE
Authors: Symeon Missios, Kimon Bekelis
Journal: Neuro-Oncology (2015)

INTRODUCTION: There is increasing regulatory pressure for cost containment in neuro-oncology, and rationalization of the observed regional disparities.We investigated the presence of such disparities in New York State and examined the impact of risk adjustment on the magnitude of this variation.METHODS: We performed a cohort study involving patients with brain tumors (gliomas, metastases, or meningiomas), who underwent craniotomy for resection from 2009-2013, and were registered in the Statewide Planning and Research Cooperative System (SPARCS) database.A linear regression model was utilized for risk-adjustment of inpatient charges using patient's age, race, insurance status, number of inpatient procedures, tumor type, length of stay, and several comorbidities as covariates.Hospitals with fewer than 20 craniotomies were excluded.RESULTS: 13,535 patients underwent treatment, including 5,032 (37.2%) gliomas, 4,858 (35.9%) metastases, and 3,645 (26.9%) meningiomas.Unadjusted median hospitalization charges ranged from $22,954 to $177,398 at the hospital level, and $30,086 to $159,281 at the county level.Despite extensive risk-adjustment we observed persistent disparities with median hospitalization charges ranging from $65,760 to $100,493 at the hospital level, and $52,104 to $92,650 at the county level.Analysis of variance (ANOVA) demonstrated that these disparities were significant at the facility and the county level (P , 0.0001).CONCLUSIONS: Using a comprehensive all-payer cohort of patients with brain tumors in New York State we identified wide disparities at the hospital and the county level despite comprehensive risk-adjustment.Further research is needed to identify the characteristics of the better performing institutions.
Progression-free survival and time to progression as surrogate markers of overall survival in patients with advanced gastric cancer: Literature-based analysis of 36 randomized trials.
Authors: K. Shitara, J. Ikeda, A. Mizota, C. Kondo, M. Nomura, T. Yokota, D. Takahari, T. Ura, K. Muro, K. Matsuo
Journal: Journal of Clinical Oncology (2011)

103 Background: We evaluated the potential of progression-free survival (PFS) and time to progression (TTP) to act as surrogates of overall survival (OS) in clinical trial settings by a comprehensive literature-based analysis. Methods: Randomized trials of systemic chemotherapy for advanced gastric cancer were identified by comprehensive electronic and manual search. Correlations between PFS/TTP and OS were evaluated. Results: Thirty-six trials with a total of 83 treatment arms and 10,484 patients were selected for analysis. The nonparametric Spearman rank correlation coefficient (p) between median PFS/TTP and OS was 0.70 (95% CI, 0.59 to 0.82) and the correlation coefficient between hazard ratios in PFS/TTP and OS was 0.80 (95% CI, 0.68 to 0.92). Correlation tended to be higher in non-Asian (p = 0.80; 0.61-0.98) than Asian trials (p = 0.67; 0.39-0.94), higher in trials reporting PFS (p = 0.85; 0.72-0.97) than in those reporting TTP (p = 0.60; 0.24-0.97), and higher in trials in patients with measurable lesions only (p = 0.91; 0.77-1.00) than in those including non-measurable lesions (p = 0.71; 0.50-0.93), albeit that none of these differences was significant. Conclusions: Our results indicate that improvements in PFS/TTP in advanced gastric cancer strongly correlate with improvements in OS. PFS/TTP may be an appropriate surrogate for OS in clinical trials for advanced gastric cancer. No significant financial relationships to disclose.
Clinical Nutrition and Feeding in Infancy and Childhood.
Journal: JAMA (1930)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
RTRB-13REVIEW OF GLIOMATOSIS CEREBRI IN SINGLE INSTITUTION
Authors: Isao Ono, Yoshiki Arakawa, Takeharu Kunieda, Yasushi Takagi, Susumu Miyamoto, Masahiro Tanji, Yohei Mineharu
Journal: Neuro-Oncology (2015)

OBJECTIVE: Gliomatosis cerebri (GC) is a diffusely infiltrating glial neoplasm of the brain.Radiotherapy for GC can be associated with improved survival, but the optimal therapy for GC is unclear.The aim of this study is to investigate the clinical result of GC after radiotherapy with/without chemotherapy and evaluate the recurrence pattern on focal radiation and whole brain radiation.PATIENTS AND METHODS: Between October 2006 and May 2015, 17 GC patients were diagnosed by MRI and biopsy.All patients received focal radiation to the tumor or whole brain radiation.Retrospectively, we reviewed 14 patients who were surveyed.RESULTS: Four patients received focal radiation and 10 patients received whole brain radiation.Mean progression free survival and overall survival in focal radiation group and whole brain radiation group were 17.3 and 16.8 months, respectively (p ¼ 0.95).The recurrence without apparent anatomical relation to primary lesion had developed in 2 patients of focal radiation group and 3 patients of whole brain radiation group (p¼ 0.73).CONCLUSION: In the clinical outcomes of GC, there were no significant differences between focal radiation and whole brain radiation.Efficacy of chemotherapy is unclear in our series.
Study of the Expression of Angiogenic Factors and Dopaminergic Receptors: Correlation with ZAP70, CD38 and the Mutational State in Chronic Lymphocytic Leukaemia (CLL).
Authors: Pilar Eroles, Isabel Benet, Isabel Marugan, Ana Belen Teruel, Carlos Solano, Maria Jose Terol
Journal: Blood (2006)
Eltrombopag Can Stimulate Trilineage Hematopoiesis with Transfusion Independence in Patients with Refractory Severe Aplastic Anemia: Results From a Phase II Trial
Authors: Matthew J. Olnes, Phillip Scheinberg, Katherine Calvo, Yong Tang, Susan Soto, Xingmin Feng, Ronan G. Desmond, Jay N. Lozier, Neal S. Young, Cynthia E. Dunbar
Journal: Blood (2011)
Tdp-43 cryptic exons are highly variable between cell types
Authors: Yun Ha Jeong, Jonathan P. Ling, Sophie Z. Lin, Aneesh N. Donde, Kerstin E. Braunstein, Elisa Majounie, Bryan J. Traynor, Katherine D. LaClair, Thomas E. Lloyd, Philip C. Wong
Journal: Molecular Neurodegeneration (2017)

TDP-43 proteinopathy is a prominent pathological feature that occurs in a number of human diseases including amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and inclusion body myositis (IBM). Our recent finding that TDP-43 represses nonconserved cryptic exons led us to ask whether cell type-specific cryptic exons could exist to impact unique molecular pathways in brain or muscle. In the present work, we investigated TDP-43's function in various mouse tissues to model disease pathogenesis. We generated mice to conditionally delete TDP-43 in excitatory neurons or skeletal myocytes and identified the cell type-specific cryptic exons associated with TDP-43 loss of function. Comparative analysis of nonconserved cryptic exons in various mouse cell types revealed that only some cryptic exons were common amongst stem cells, neurons, and myocytes; the majority of these nonconserved cryptic exons were cell type-specific. Our results suggest that in human disease, TDP-43 loss of function may impair cell type-specific pathways.
Comparative High Resolution Array-Based CGH (aCGH) in B-Cell Malignancies.
Authors: Esteban Braggio, Jonathan J. Keats, Wee-Joo Chng, Victor H. Jimenez, Roelandt Schop, Alexander Sekulik, Angela Baker, Scott Van Wier, Tammy Price-Troska, Michael Barrett, John Carpten, Ellen Remstein, Ahmet Dogan, Leif P. Bergsagel, Rafael Fonseca
Journal: Blood (2007)
Twenty-five percent positive biopsy rate in a high risk prostate cancer screening program with a PSA ≤ 2.5 ng/ml
Authors: A. A. Konski, S. Feigenberg, S. Raysor, D. Eisenberg, I. Mirchandani, R. G. Uzzo, R. Greenberg, E. Horwitz, A. Pollack, G. Hanks, D. Watkins-Bruner
Journal: Journal of Clinical Oncology (2005)

4557 Background: African-American (AA) males and Caucasian males with a family history of prostate cancer (PCA) have been shown to be at increased risk of developing prostate cancer. We report the results of the first 520 males enrolled in a high-risk prostate cancer screening program. Methods: AA men and Caucasian men with at least one first-degree or ≥ 2 second degree relatives diagnosed with PCA between the ages of 35 and 69 were eligible for enrollment into the Prostate Cancer Risk Assessment Program. Caucasian men testing positive for the BRAC1 gene were also eligible. Biopsy criteria included abnormal DRE, PSA >4 ng/ml and PSA ≥ 2 & <4 and free PSA <22%. Investigated variables between groups included: race, family history, income, education level, marital status, PSA and Gleason score in patients diagnosed with cancer. A chi-square test, t-test and ANOVA were used to test significance between groups and investigated variables. Results: A total of 520 men, 200 Caucasian, 315 AA men, and 5 men of other races were enrolled between 10/96 and 9/04. A total of 75 men, 44 AA and 31 Caucasian, underwent 101 biopsies. The median age at biopsy was 56 (37–73). The median PSA at biopsy was 3.5 (0.4–53.6 ng/ml) with a median percent free PSA (fPSA) of 15 (3.5–29). PCA was found in 45% percent of men biopsied, with 26% of patients with PCA having Gleason score of ≥ 7. Twenty-five percent (11/44) of patients with a PSA ≤ 2.5 ng/ml had PCA with a marginally significant lower fPSA compared to patients with negative biopsies, (p=0.0642). Logistic regression found the lower the fPSA the more likely the diagnosis of PCA. Conclusions: Our biopsy criteria resulted in a diagnosis of PCA in 45% overall and 25% of men with a PSA ≤ 2.5 ng/ml in a high-risk screening program undergoing biopsy. 25% of the men diagnosed with PCA would have had a PSA below the newly recommended NCCN screening guideline. Aggressive screening parameters are appropriate for men at high-risk for developing PCA. No significant financial relationships to disclose.
Durable Engraftment with Minimal Toxicities after Allogeneic Hematopoietic Stem Cell Transplantation with a Reduced-Intensity Regimen Incorporating Fludarabine and 8 mg/kg Busulfan.
Authors: Naoyuki Uchida, Takahiro Fukuda, Atsushi Wake, Sung-Won Kim, Kazuhiro Masuoka, Shin-ichiro Mori, Shigesaburo Miyakoshi, Ryuji Tanosaki, Yoichi Takaue, Shuichi Taniguchi
Journal: Blood (2006)